Contineum Therapeutics, Inc. (CTNM)

Market Cap	456.25M +168.6%
Revenue (ttm)	n/a
Net Income	-59.98M
EPS	-2.17
Shares Out	37.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	451,436
Open	13.16
Previous Close	13.22
Day's Range	12.03 - 13.16
52-Week Range	3.35 - 16.33
Beta	n/a
Analysts	Buy
Price Target	19.80 (+62.03%)
Earnings Date	Mar 5, 2026

About CTNM

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitt...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 5, 2024
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: CTNM
• Website: https://www.contineum-tx.com

Analyst Summary

According to 5 analysts, the average rating for CTNM stock is "Buy." The 12-month stock price target is $19.8, which is an increase of 62.03% from the latest price.

Price Target

$19.8

(62.03% upside)

Analyst Consensus: Buy